Comparing sacituzumab tirumotecan to standard chemotherapy for advanced lung cancer
Official title: A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors
Run by Merck Sharp & Dohme LLC · NCT06305754 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study tests if a new drug called sacituzumab tirumotecan can help people with advanced lung cancer live longer and feel better compared to standard chemotherapy.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 520 (estimated) |
| Sponsor | Merck Sharp & Dohme LLC Industry-sponsored |
| Drugs / interventions | radiation, sacituzumab, chemotherapy |
| Locations | 156 sites (Oakland, California and 155 other locations) |
| Trial ID | NCT06305754 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals with advanced nonsquamous NSCLC who have progressed on prior EGFR tyrosine kinase inhibitors.
✕Probably not a fit
Patients with predominantly squamous cell histology NSCLC or those with significant peripheral neuropathy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of sacituzumab tirumotecan compared to a combination of pemetrexed and carboplatin in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) who have not responded to previous EGFR tyrosine kinase inhibitors. Participants will be randomly assigned to receive either the experimental drug or the standard chemotherapy regimen. The primary goals are to assess progression-free survival and overall survival between the two treatment groups.
Why it matters
Potential benefit: If successful, this treatment could offer a more effective option for patients with advanced NSCLC who have exhausted prior therapies.
How similar studies have gone: Other studies have shown promising results with similar approaches, but this specific comparison is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of advanced-stage nonsquamous non-small cell lung cancer (NSCLC). * Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade ≤1 or baseline. * Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load. * Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable. * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy. * Life expectancy of at least 3 months. Exclusion Criteria: * Predominantly squamous cell histology NSCLC. * History of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years. * Grade ≥2 peripheral neuropathy. * History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing. * Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease. * Uncontrolled, or significant cardiovascular disease or cerebrovascular disease. * Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids. * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed. * Received radiation therapy to the lung that is \>30 Gray within 6 months of the first dose of study intervention. * Known active central nervous system metastases and/or carcinomatous meningitis. * Active infection requiring systemic therapy. * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease. * Concurrent active HBV and HCV infection. * History of allogeneic tissue/solid organ transplant. * Participants who have not adequately recovered from major surgery or have ongoing surgical complications.
Where it's running
-
Kaiser Permanente - Oakland ( Site 0054)
Oakland, California, United States Recruiting -
Kaiser Permanente - Roseville ( Site 0055)
Roseville, California, United States Recruiting -
Kaiser Permanente - San Francisco ( Site 0056)
San Francisco, California, United States Recruiting -
Kaiser Permanente - Santa Clara ( Site 0057)
Santa Clara, California, United States Recruiting -
Kaiser Permanente-Kaiser Permanente ( Site 0036)
Vallejo, California, United States Recruiting -
Kaiser Permanente - Walnut Creek ( Site 0058)
Walnut Creek, California, United States Recruiting
Show 44 more locations
-
Mid Florida Hematology and Oncology Center ( Site 0005)
Orange City, Florida, United States Recruiting -
University of Michigan ( Site 0009)
Ann Arbor, Michigan, United States Recruiting -
Cox Medical Center North - Cox Medical Center/ Hematology/Medical Oncology ( Site 0051)
Springfield, Missouri, United States Recruiting -
Astera Cancer Care ( Site 0032)
East Brunswick, New Jersey, United States Recruiting -
Stony Brook University-Cancer Center ( Site 0038)
Stony Brook, New York, United States Recruiting -
Sanford Fargo Medical Center ( Site 0028)
Fargo, North Dakota, United States Recruiting -
Sanford Cancer Center ( Site 0024)
Sioux Falls, South Dakota, United States Recruiting -
John Peter Smith Hospital ( Site 0065)
Fort Worth, Texas, United States Recruiting -
University of Texas MD Anderson ( Site 0063)
Houston, Texas, United States Recruiting -
Clinica Adventista Belgrano-Oncology ( Site 0315)
Caba., Buenos Aires, Argentina Recruiting -
Instituto Alexander Fleming ( Site 0307)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina Recruiting -
Hospital Británico de Buenos Aires-Oncology ( Site 0304)
Buenos Aires, Buenos Aires F.D., Argentina Recruiting -
Centro Privado de RMI Río Cuarto S.A. II ( Site 0310)
Río Cuarto, Córdoba Province, Argentina Recruiting -
Instituto de Oncología de Rosario ( Site 0301)
Rosario, Santa Fe Province, Argentina Recruiting -
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0303)
La Rioja, Argentina Recruiting -
Cross Cancer Institute ( Site 0201)
Edmonton, Alberta, Canada Recruiting -
Waterloo Regional Health Network (WRHN) ( Site 0207)
Kitchener, Ontario, Canada Recruiting -
Princess Margaret Cancer Centre ( Site 0203)
Toronto, Ontario, Canada Recruiting -
McGill University Health Centre ( Site 0204)
Montreal, Quebec, Canada Recruiting -
FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0600)
Bogotá, Bogota D.C., Colombia Recruiting -
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0606)
Bogotá, Bogota D.C., Colombia Recruiting -
Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0601)
Valledupar, Cesar Department, Colombia Recruiting -
IMAT S.A.S ( Site 0602)
Montería, Departamento de Córdoba, Colombia Recruiting -
Oncologos del Occidente ( Site 0604)
Pereira, Risaralda Department, Colombia Recruiting -
Fundacion Valle del Lili- CIC-Oncology CIC ( Site 0605)
Cali, Valle del Cauca Department, Colombia Recruiting -
Nouvel Hôpital Civil (NHC) ( Site 1302)
Strasbourg, Alsace, France Recruiting -
Clinique Clairval ( Site 1306)
Marseille, Bouches-du-Rhone, France Recruiting -
Hopitaux Universitaires Paris Centre-Hopital Cochin-Unité d'Oncologie Thoracique ( Site 1304)
Paris, France Recruiting -
Gustave Roussy ( Site 1303)
Villejuif, Île-de-France Region, France Recruiting -
Artemis hospital ( Site 3307)
Gurugram, Haryana, India Recruiting -
Tata Memorial Hospital-Medical Oncology ( Site 3304)
Mumbai, Maharashtra, India Recruiting -
All India Institute of Medical Sciences-Department of medical oncology ( Site 3303)
New Delhi, National Capital Territory of Delhi, India Recruiting -
Instituto Tumori Giovanni Paolo II-SSD Oncologia Medica per la Patologia Toracica ( Site 1802)
Bari, Apulia, Italy Recruiting -
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1800)
Milan, Lombardy, Italy Recruiting -
Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 1803)
Milan, Lombardy, Italy Recruiting -
Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1804)
Florence, Tuscany, Italy Recruiting -
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1801)
Roma, Italy Recruiting -
Fujita Health University Hospital ( Site 3409)
Toyoake, Aichi-ken, Japan Recruiting -
Ehime University Hospital ( Site 3411)
Tōon, Ehime, Japan Recruiting -
National Hospital Organization Kyushu Cancer Center ( Site 3401)
Fukuoka, Fukuoka, Japan Recruiting -
Gunma Prefectural Cancer Center ( Site 3413)
Ōta, Gunma, Japan Recruiting -
Kanazawa University Hospital ( Site 3402)
Kanazawa, Ishikawa-ken, Japan Recruiting -
St. Marianna University Hospital ( Site 3415)
Kawasaki, Kanagawa, Japan Recruiting -
Kanagawa Cancer Center ( Site 3416)
Yokohama, Kanagawa, Japan Recruiting
+106 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: Toll Free Number
- Email: Trialsites@msd.com
- Phone: 1-888-577-8839
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Combining sacituzumab tirumotecan with pembrolizumab for advanced lung cancer
This study is testing if combining two cancer treatments, sacituzumab tirumotecan and pembrolizumab, can help people with advanced lung cancer live longer compared to just using pembrolizumab alone.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
NSCLC biomarker study using tumor and blood samples to link genetics with prognosis and immunotherapy response
Researchers will test tumor tissue and blood from about 300 NSCLC patients to find genomic and immune markers that predict prognosis and response to immunotherapy.
-
Sacituzumab Tirumotecan plus Pembrolizumab in advanced biliary tract cancer
This study tests whether the combination of Sacituzumab Tirumotecan and Pembrolizumab can help people with advanced biliary tract cancer who have already had at least one approved therapy fail.
-
Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion
This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.
-
Sacituzumab Govitecan plus Tislelizumab for advanced esophageal cancer
This phase II study tests whether the cancer-fighting drug sacituzumab tirumotecan (SKB264) combined with tislelizumab can help adults with advanced esophageal squamous cell carcinoma that progressed after initial immunotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.